BAGSVAERD, DENMARK--(Marketwired - Aug 8, 2013) - Sales increased by 14% in local currencies and by 11% in Danish kroner to DKK 41.4 billion.- Sales of modern insulins increased by 15% (13% in Danish kroner).- Sales of Victoza® increased by 32% (30% in Danish kroner).- Sales in North America increased by 23% (21% in Danish kroner).- Sales in International Operations increased by 17% (12% in Danish kroner).Company announcemen No 54 / 2013: http://hugin.info/2013/R/1721833/573536.pdfThis announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Novo Nordisk A/S via Thomson Reuters ONE[HUG#1721833]